Hertab 250mg Tablet 150's

About

Hertab 250mg Tablet is a targeted therapy, functioning as a dual tyrosine kinase inhibitor that specifically blocks the activity of both epidermal growth factor receptor (EGFR, ErbB1) and human epidermal growth factor receptor 2 (HER2, ErbB2). These receptor tyrosine kinases are frequently overexpressed or hyperactive in certain cancers, particularly HER2-positive breast cancer, where they drive uncontrolled cell proliferation, survival, and metastasis. By inhibiting the intracellular phosphorylation of these receptors, Hertab effectively disrupts the downstream signaling pathways crucial for cancer cell growth. This interference leads to reduced tumor cell proliferation and increased apoptosis. It is typically utilized in combination with other chemotherapeutic or hormonal agents for the treatment of advanced or metastatic HER2-positive breast cancer, offering a crucial therapeutic option for patients with this aggressive subtype.

Uses

• HER2-positive metastatic breast cancer
• Hormone receptor-positive, HER2-positive breast cancer
• Advanced solid tumors with HER2 overexpression
• As part of combination therapy regimens

Directions For Use

Take orally as prescribed by your doctor, usually once daily. It may be taken with or without food, depending on specific instructions.

Benefits

• Targets specific cancer pathways (EGFR/HER2)
• Effective in HER2-positive breast cancer
• Oral administration for convenience
• Can be used in combination therapy
• May overcome resistance to other treatments
• Slows disease progression

Side Effects

• Diarrhea
• Rash
• Nausea
• Vomiting
• Fatigue
• Hand-foot syndrome
• Stomatitis
• Anorexia
• Dry skin
• Cardiac dysfunction (rare, but serious)
• Hepatotoxicity
• Interstitial lung disease (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate gastrointestinal side effects or liver toxicity.
• Pregnancy - Not recommended during pregnancy due0 to potential fetal harm. Effective contraception is required for women of childbearing potential.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary. Monitor liver function closely.
• Kidney - Use with caution in patients with renal impairment; dose adjustments are generally not required but monitor closely.
• Lung - Monitor for signs of interstitial lung disease or pneumonitis, though rare, as it can be serious.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.